Skip to main content

Branded

  • Biogen Idec hopes treatment will be first advance in hemophilia B treatment in 15 years

    WESTON, Mass. — Biogen Idec is seeking Food and Drug Administration approval for a hemophilia drug that it called the first of its kind.

    The drug maker announced that it had submitted a regulatory application for recombinant factor IX Fc fusion protein, or rFIXFc, which it called the first long-lasting factor IX therapy for hemophilia B.

  • Study: Consumers equate high cost of flu shot to low risk of getting the flu

    NEW ORLEANS — Consumers measure the risk of contracting the flu to the price of their flu shot, according to research out of Tulane University released Friday. 

    The study found that consumers make judgments about their risk of catching any illness based on the cost of its medication. The higher the price, the less they think they’re at risk, stated co-author Janet Schwartz, assistant professor of marketing at Tulane’s A.B. Freeman School of Business.

  • CDC launches official influenza app for health professionals

    ATLANTA — The Centers for Disease Control and Prevention on Monday announced the launch of its CDC Influenza application for clinicians and other healthcare professionals on the Apple platform. The app makes it easy to access CDC’s latest recommendations and influenza activity updates on an iPad, iPhone or iPod Touch, the agency stated.

    An Android support will be added in a future update, CDC noted. 

  • FDA approves new delivery method for MS drug

    NEW YORK — The Food and Drug Administration has approved a new means of administration for a multiple sclerosis drug, the manufacturers said.

    Pfizer and EMD Serono announced the approval of Rebif Rebidose (interferon beta-1a), a single-use auto-injector for self-administering Rebif, used to treat relapsing forms of MS. EMD Serono is the U.S. division of German drug maker Merck KGaA, so-named to avoid confusion with U.S.-based Merck & Co.

  • Novo Nordisk appoints Curtis Oltmans as corporate VP, general counsel for legal and quality affairs

    PRINCETON, N.J. — Novo Nordisk has appointed Curtis Oltmans as its corporate VP and general counsel for legal and quality affairs, the company said Friday.

    In the new role, for which he will also join the company's U.S. executive team, Oltmans will be handle issues like law, quality, intellectual property, grants and philanthropy for the Danish drug maker's North American business.

  • Mintel: Declining user base means smoking cessation aids will experience slow growth through 2017

    CHICAGO — Sales of smoking cessation aids are projected to reach $1 billion in 2012 with continued growth driving sales as high as $1.2 billion by 2017, market research firm Mintel reported Thursday. 

  • March of Dimes highlights folic acid for pregnant women

    WHITE PLAINS, N.Y. — The March of Dimes is launching a campaign to encourage expectant mothers to take folic acid to prevent birth defects, the group said Friday.

    The group announced national Folic Acid Awareness Week, reminding pregnant women to take vitamin B. The vitamin is known to prevent birth defects like spina bifida and anencephaly, collectively known as neural tube defects. NTDs occur in the first few weeks following conception, often before a woman knows she is pregnant.

  • Bloomberg: B&L on sales block for as much as $10 billion

    NEW YORK — According to a Bloomberg report published Friday morning, Abbott Laboratories, Johnson & Johnson and Sanofi are all potential suitors for Bausch & Lomb's eye care business in a deal that could be valued as high as $10 billion. 

    B&L is being shopped by private equity firm Warburg Pincus, which is working with Goldman Sachs Group, Bloomberg reported, and both Abbott and Sanofi have contracted financial advisors as well. 

    Other companies who have been invited to bid include Merck and Pfizer. 

X
This ad will auto-close in 10 seconds